Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunyan Song

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
Eclinicalmedicine|August 26, 2020
Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort studyDan Liu, Pengfei Cui, Shaoqing Zeng, et al.
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
The New England Journal of Medicine|October 30, 2024
Inavolisib-Based Therapy in <i>PIK3CA</i>-Mutated Advanced Breast CancerNicholas C Turner, Seock-Ah Im, Cristina Saura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.
Clinical and Translational Medicine|July 23, 2020
Alteration of serum markers in COVID-19 and implications on mortalityDan Liu, Ruyuan Li, Ruidi Yu, et al.
The Lancet. Digital Health|February 26, 2022
Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic studyYue Gao, Shaoqing Zeng, Xiaoyan Xu, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
Eclinicalmedicine|August 26, 2020
Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort studyDan Liu, Pengfei Cui, Shaoqing Zeng, et al.
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
The New England Journal of Medicine|October 30, 2024
Inavolisib-Based Therapy in <i>PIK3CA</i>-Mutated Advanced Breast CancerNicholas C Turner, Seock-Ah Im, Cristina Saura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.
Clinical and Translational Medicine|July 23, 2020
Alteration of serum markers in COVID-19 and implications on mortalityDan Liu, Ruyuan Li, Ruidi Yu, et al.
The Lancet. Digital Health|February 26, 2022
Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic studyYue Gao, Shaoqing Zeng, Xiaoyan Xu, et al.
Pageof 11